These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26004600)

  • 1. Therapeutic challenge during the long-term follow-up of a patient with indolent systemic mastocytosis with extensive cutaneous involvement.
    Marton I; Pósfai É; Borbényi Z; Bödör C; Papp G; Demeter J; Korom I; Varga E; Bata-Csörgő Z
    Eur Rev Med Pharmacol Sci; 2015; 19(9):1607-9. PubMed ID: 26004600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin lesions and mast cells.
    Blood; 2008 Jul; 112(1):28. PubMed ID: 18584778
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of imatinib in the treatment of pediatric onset indolent systemic mastocytosis: a case report.
    Agarwala MK; George R; Mathews V; Balasubramanian P; Thomas M; Nair S
    J Dermatolog Treat; 2013 Dec; 24(6):481-3. PubMed ID: 23659595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical observations in cutan mastocytosis].
    Mihalik N; Hidvégi B; Hársing J; Várkonyi J; Csomor J; Kovalszky I; Marschalkó M; Kárpáti S
    Orv Hetil; 2013 Sep; 154(37):1469-75. PubMed ID: 24016753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.
    Droogendijk HJ; Kluin-Nelemans HJ; van Doormaal JJ; Oranje AP; van de Loosdrecht AA; van Daele PL
    Cancer; 2006 Jul; 107(2):345-51. PubMed ID: 16779792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vulvar oedema revealing systemic mastocytosis].
    Deveza E; Locatelli F; Girardin M; Valmary-Degano S; Daguindau E; Aubin F; Humbert P; Pelletier F
    Ann Dermatol Venereol; 2015 Nov; 142(11):685-9. PubMed ID: 26003033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: Are we there yet?
    Akin C; Arock M; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1912-1918. PubMed ID: 35487307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis.
    Broderick V; Waghorn K; Langabeer SE; Jeffers M; Cross NCP; Hayden PJ
    Leuk Res; 2019 Feb; 77():28-29. PubMed ID: 30612056
    [No Abstract]   [Full Text] [Related]  

  • 10. Sustained improvement in urticaria pigmentosa and pruritus in a case of indolent systemic mastocytosis treated with cladribine.
    Lock AD; McNamara CJ; Rustin MH
    Clin Exp Dermatol; 2015 Mar; 40(2):142-5. PubMed ID: 25515765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.
    Florian S; Krauth MT; Simonitsch-Klupp I; Sperr WR; Fritsche-Polanz R; Sonneck K; Födinger M; Agis H; Böhm A; Wimazal F; Horny HP; Valent P
    Int Arch Allergy Immunol; 2005 Mar; 136(3):273-80. PubMed ID: 15722637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Systemic mastocytosis].
    Niedoszytko M; Lange M; Chelminska M; Jaśkiewicz K; Piskosz A; Wasag B; Lewandowski K; Mital A; Renke J; Gruchała-Niedoszytko M; Woźniak M; Babińska A; Jassem E
    Pneumonol Alergol Pol; 2005; 73(3):239-44. PubMed ID: 16989160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib.
    Zhao DD; Zhang L; Li WQ; Duan MH; Zhuang JL; Zhou DB
    Chin Med J (Engl); 2019 Aug; 132(16):2002-2003. PubMed ID: 31335472
    [No Abstract]   [Full Text] [Related]  

  • 14. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
    de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
    Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Systemic mastocytosis. Classification, symptoms, therapy].
    Kraemer DM; Grunewald SM; Kolb-Mäurer A
    Med Klin (Munich); 2004 Mar; 99(3):131-6. PubMed ID: 15024485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous mastocytosis: A dermatological perspective.
    Di Raimondo C; Del Duca E; Silvaggio D; Di Prete M; Lombardo P; Mazzeo M; Spallone G; Campione E; Botti E; Bianchi L
    Australas J Dermatol; 2021 Feb; 62(1):e1-e7. PubMed ID: 33040350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Mastocytosis: The Difficult Patient with a Rare Disease. Case Presentation and Brief Review.
    Desmond DH; Carmichael MG
    Hawaii J Med Public Health; 2018 Feb; 77(2):27-29. PubMed ID: 29435387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic mastocytosis: current concepts and treatment advances.
    Tefferi A; Pardanani A
    Curr Hematol Rep; 2004 May; 3(3):197-202. PubMed ID: 15087068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
    Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
    J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent syncope and anaphylaxis as presentation of systemic mastocytosis in a pediatric patient: case report and literature review.
    Shaffer HC; Parsons DJ; Peden DB; Morrell D
    J Am Acad Dermatol; 2006 May; 54(5 Suppl):S210-3. PubMed ID: 16631942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.